PAGE 11
HIV NUTRITION UPDATE
VOLUME 8, ISSUE 1
A Review Of Coenzyme Q10

(Continued from page 10)

CONCLUSION

The studies available indicate there is inadequate information on the impact of HIV infection on CoQ10 metabolism and they lack evidence that CoQ10 supplementation repletes deficient levels. There is also no data on the potential impact of ARV’s or HAART on these same parameters. Consequently, at this time, there is no evidence to support the contention that CoQ10 supplementation slows HIV/AIDS progression. However, independent of its potential role in HIV infection, evidence exists that CoQ10 metabolism may be impacted by conventional therapies of other HIV-related conditions. For example, both oral antidiabetics and the hypocholesterolemic class of agents, HMG CoA reductase inhibitors, are reported to interfere with CoQ10 synthesis. Several reviews contain reports of efficacious use of adjunctive CoQ10 for management of heart failure. Based on these reports, use of CoQ10 could be considered for PWHIV taking HMG CoA reductase inhibitors or for whom a cardioprotective agent may be beneficial. Additional studies are clearly needed to clarify the role of CoQ10 in HIV infection.

 
References

1. Langsjoen PH. Introduction To Coenzyme Q10. Tyler, TX;1994. Accessed 22 March 2003.

2. Sahelian R. Frequently Asked Questions All About Coenzyme Q10. Garden City Park, NY:Avery Publishing Group;1998.

3. Ely JTA. A Physicians' Update On Coenzyme Q10 In U.S. Medicine.  Summary Of A Recent Medline Search And Other Materials.

4. Larsen HR. Coenzyme Q10: The Wonder Nutrient. International Health News 2000.  Int J Alt Comp Med 1998;16(2):11-12. Accessed 2 Oct 2000.

5. Overvad K, Diamant B, Holm L. Review: Coenzyme Q10 In Health And Disease. Eur J Clin Nutr 1999;53:764-770. 

6. Pelton R, LaValle JB, Hawkins EB, Krinsky DL, Editors. Drug-Induced Nutrient Depletion Handbook 1999-2000. Lexi-Comp:Hudson, OH; 1999:256-259.

7. Jellin JM, Gregory P, Batz F, et al. Coenzyme Q-10. In: Pharmacist's Letter/Prescriber's Letter Natural Medicines Comprehensive Database. Third edition. Stockton, CA: Therapeutic Research Faculty; 2000:302-303.

8. Lister RE. An Open Pilot Study To Evaluate The Potential Benefits Of Coenzyme Q10 Combined With Ginkgo Biloba Extract In Fibromyalgia Syndrome. J Int Med Res 2002;30(2):195-199.

9. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open Label Trial Of Coenzyme Q10 As A Migraine Preventive. Cephalalgia 2002;22(2):137-141.

10. CoEnzyme Q10. Natural Standard Patient Monograph. University of Texas M. D. Anderson Cancer Center; September 2002. Accessed 27 Feb 2003.

11. Cahn J, Borzeix MG, Angignard J, et al. Possible Use Of Coenzyme Q10 In Acute Cerebral Disease. In: Folkers K, Yamamura Y, Editors. Biomedical And Clinical Aspects Of Coenzyme Q. Amsterdam:Elsevier 1981;3:385-395.

12. Ogawa N, Tsukamoto S, Hirose Y. Survival Effect Of Coenzyme Q10 And Naloxone On Experimental Stroke Gerbils. Pharmacol Biochem Behav 1986;24(2):315-317.

13. Langsjoen PH, Vadhanavikit S, Folkers K. Effective Treatment With Coenzyme Q10 Of Patients With Chronic Myocardial Disease. Drugs Exp Clin Res 1985;11(8):577-579. 

14. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical Rationale And Myocardial Tissue Data On The Effective Therapy Of Cardiomyopathy With Coenzyme Q10. Proc Natl Acad Sci USA 1985;82(3):901-904.

15. Langsjoen PH, Vadhanavikit S, Folkers K. Response Of Patients In Classes III And IV Of Cardiomyopathy To Therapy In A Blind And Crossover Trial With Coenzyme Q10. Proc Natl Acad Sci USA 1985;82(12):4240-4244.

16. Langsjoen PH, Folkers K, Lyson K, et al. Effective And Safe Therapy With Coenzyme Q10 For Cardiomyopathy. Klin Wochenschr 1988;66(13):583-90.

17. Langsjoen PH, Langsjoen PH, Folkers K. A Six-Year Clinical Study Of Therapy Of Cardiomyopathy With Coenzyme Q10. Int J Tissue React 1990;12(3):169-71.

18. Langsjoen PH, Folkers K, Lyson K, et al. Pronounced Increase Of Survival Of Patients With Cardiomyopathy When Treated With Coenzyme Q10 And Conventional Therapy. Int J Tissue React 1990;12(3): 163-168. 

19. Langsjoen PH, Langsjoen PH, Folkers K. Long-Term Efficacy And Safety Of Coenzyme Q10 Therapy For Idiopathic Dilated Cardiomyopathy. Am J Cardiol 1990;65(7):521-523. 

20. Folkers K, Langsjoen P, Langsjoen PH. Therapy With Coenzyme Q10 Of Patients In Heart Failure Who Are Eligible Or Ineligible For A Transplant. Biochem Biophys Res Commun 1992;182(1):247-53.

21. Judy WV, Stogsdill WW, Folkers K. Myocardial Preservation By Therapy With Coenzyme Q10 During Heart Surgery. Clin Investig 1993;71(8 Suppl):S155-S161. 

22. Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness Of Coenzyme Q10 In Clinical Cardiology: A Long-Term Study. Mol Aspects Med 1994;15 Suppl:s165-s175. 

23. Folkers K. The Potential Of Coenzyme Q 10 (NSC-140865) In Cancer Treatment. Cancer Chemother 1974;Rep 2 4 (4):19-22.
(Continued on page 19)

 
 
 
 
 
 
 
 
 
 
 
 
 "It is best to split your CoQ10 dosage. If you are planning to take 60 mg per day, take 30 mg with breakfast and 30 mg with lunch."

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
"NUMEDX Hepatitis is now freely available on the Internet!" 

 


 
 

 
 
Copyright 2003 HIV ReSources, Inc. Sharing this newsletter in any form with non-subscribers is strictly prohibited. Library/Institution subscribers are permitted to share HIV Nutrition Update html newsletter pages with up to five (5) employees or volunteers. NO other redistribution allowed. 
 
Please Help To Keep This Page Updated By Notifying
The Webmaster If You Find A Link That's Outdated!
 
HIV ReSources, Inc.
PO Box 39385
Fort Lauderdale, FL
33339-9385
USA
 
© 2003  HIV ReSources, Inc.
Any use of the information presented herein is done strictly at your own risk.
No responsibility is implied or intended on the part of HIV ReSources Inc,
the editor, or the publisher. Information on this site should not
be construed as an endorsement of any kind.
 
7/30/2003